Merck & Co., Inc.
MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30250% above fair value
$149.52+3.19 (+2.18%)
Close on Oct 30, 2026Market cap $368.89BP/E 119.6Yield 2.19%
Merck Nasonex by Quarter
Nasonex (mometasone, legacy pre-Organon spin-off) — International reported growth YoY (%) (%)
Merck Nasonex: -37.0% in Q1 2021, down 4.0 pts from a year earlier. No newer figure appears in the documents we track.
Latest, Q1 2021
-37.0%
Period ended Mar 31, 2021
Change on a year earlier
-4.0 pts
-33.0% in Q1 2020
History
9 quarters
Since Q4 2017
Sources
9
Documents cited below
Where the Q1 2021 figure comes from
“|| Nasonex | 43 | 71 | -39 | 2 | 6 | -65 | 41 | 65 | -37”
Source: Form 8-K (tm2114316d1_ex99-1.htm, filed 2021-04-29) ↗
Reported in Form 8-K Table 3a / 3b Product Sales.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Nasonex (mometasone, legacy pre-Organon spin-off) — International reported growth YoY (%) (%) | Year on year | Source |
|---|---|---|---|---|
| Q1 2021 | Mar 31, 2021 | -37.0% | -4.0 pts | Form 8-K (tm2114316d1_ex99-1.htm, filed 2021-04-29) ↗ |
| Q2 2020 | Jun 30, 2020 | -38.0% | – | Form 8-K (tm2026006d1_ex99-1.htm, filed 2020-07-31) ↗ |
| Q1 2020 | Mar 31, 2020 | -33.0% | -13.0 pts | Form 8-K (tm2016917d1_ex99-1.htm, filed 2020-04-28) ↗ |
| Q4 2019 | Dec 31, 2019 | -31.0% | -36.0 pts | Form 8-K (tm206551d1_ex99-1.htm, filed 2020-02-05) ↗ |
| Q3 2019 | Sep 30, 2019 | -15.0% | -13.0 pts | Form 8-K (tm1921023d1_ex99-1.htm, filed 2019-10-29) ↗ |
| Q1 2019 | Mar 31, 2019 | -20.0% | – | Form 8-K (a19-8996_1ex99d1.htm, filed 2019-04-30) ↗ |
| Q4 2018 | Dec 31, 2018 | 5.0% | +11.0 pts | Form 8-K (a19-3795_1ex99d1.htm, filed 2019-02-01) ↗ |
| Q3 2018 | Sep 30, 2018 | -2.0% | – | Form 8-K (a18-37128_1ex99d1.htm, filed 2018-10-25) ↗ |
| Q4 2017 | Dec 31, 2017 | -6.0% | – | Form 8-K (a18-5152_1ex99d1.htm, filed 2018-02-02) ↗ |
Cite this data
StockData. (2026). Merck Nasonex (%), quarterly Q4 2017–Q1 2021 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev-nasonex-intl-nom-yoy
See every metric in the Merck KPI table. Data updated Oct 26, 2026.